ArticleFrontiers in genetics2025
Identifying metabolism-related genes in liver cancer through weighted gene co-expression network analysis and machine learning.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kynurenine metabolism-related gene signature for prognostic stratification in hepatocellular carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: As a leading cause of cancer-related mortality, liver cancer was associated with metabolic dysregulation. We aimed to identify metabolism-related prognostic biomarkers and therapeutic targets. Methods: Transcriptomic data from TCGA were analyzed using EdgeR to identify differentially expressed genes (DEGs). WGCNA was applied to unveil the metabolism-related genes in liver cancer. Machine learning algorithms (RF, SVM, LASSO) refined marker genes. GSEA and ssGSEA were conducted to identify pathway associations and immune interactions of marker genes. DGIdb database predicted candidate therapeutics targeting these biomarkers. The independent queue (GSE54236) was verified as an external dataset. RT-PCR validated gene expression in clinical samples. Results: A total of 234 metabolism-related genes were identified in liver cancer. Through undergoing machine learning by RF, SVM, and LASSO algorithms, seven marker genes (ACADS, ALDH8A1, COX4I2, CYP2C8, DBH, NDST3, and PLA2G6) were obtained. Except for PLA2G6, the other genes were correlated with the survival of patients with liver cancer and immune cells infiltration. Additionally, ACADS, ALDH8A1, CYP2C8, DBH, and NDST3 were downregulated, and COX4I2 was upregulated in dataset of GSE54236, which were consist with those in TCGA database. However, RT-PCR validation in 10 paired clinical samples confirmed significant downregulation of ACADS, ALDH8A1, COX4I2, CYP2C8, DBH, and NDST3 in tumor tissues (all P < 0.05). Immune infiltration analysis revealed these genes might influence immune cell infiltration in the tumor microenvironment. And the candidate drugs were unveiled, including PAZOPANIB, SUMATRIPTAN, ETOPOSIDE, etc. Conclusion: The metabolism-related biomarkers ACADS, ALDH8A1, COX4I2, CYP2C8, DBH, and NDST3 demonstrated significant potential for predicting liver cancer prognosis and may serve as candidate therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.